“We are excited to work with Elevation Oncology and look forward to working with them to strengthen their clinical trial recruitment efforts, with the ultimate goal of reducing the disease burden on NRG1-positive fusion patients in a variety of counterfeit tumors,” David said. Spetzler, MS, Ph.D., MBA, President and Chief Scientific Officer. “The long-term cancer remedy is based on current clinical trials and we are excited to use our suite of state-of-the-art precision medicine technologies to address the demanding situations generally encountered in genomic and non-tumor trials.
Under the terms of the agreement, Caris will help Elevation Oncology identify patients with complex forged tumors that harbor NRG1 fusions for participation in the Elevation Oncology CRESTONE trial. Patients eligible for their participation in the Elevation Oncology Phase 2 CRESTONE trial on seribantumab will be shown in adult patients with recurrent, complex or metastatic forged tumors that harbor NRG1 gene fusion.